# NovelStem International Corp.: financial statements, quarterly

NSTM · OTC · CIK 912544 · [Consumer discretionary](/sectors/consumer-discretionary.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/nstm.md) · [Financials](/companies/nstm/financials.md) · [Filings](/companies/nstm/filings.md) · [Insiders](/companies/nstm/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/nstm/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $k | [(548)](/filings/0001493152-24-045856.md) | [(93.6) d](/filings/0001641172-25-003031.md) | [(180)](/filings/0001641172-25-011514.md) | [(141)](/filings/0001493152-25-011661.md) | [(564)](/filings/0001493152-25-021861.md) | [(43.0) d](/filings/0001493152-26-012736.md) | [(94.6)](/filings/0001493152-26-023227.md) | [(64.0)](/filings/0001493152-26-038089.md) | [(39.5)](/filings/0001493152-25-021861.md) | [(40.7) d](/filings/0001493152-26-012736.md) | [(5.0)](/filings/0001493152-26-023227.md) | [(34.9)](/filings/0001493152-26-038089.md) |
| Interest expense | $k | [28.5](/filings/0001493152-23-041854.md) | [42.7 d](/filings/0001493152-24-012323.md) | [94.8](/filings/0001493152-24-019729.md) | [107](/filings/0001493152-25-011661.md) | [105](/filings/0001493152-25-021861.md) | [119 d](/filings/0001493152-26-012736.md) | [113](/filings/0001493152-26-023227.md) | [36.0](/filings/0001493152-25-011661.md) | [43.7](/filings/0001493152-25-021861.md) | [0.0 d](/filings/0001493152-26-012736.md) | [36.0](/filings/0001493152-26-023227.md) | [50.9](/filings/0001493152-26-038089.md) |
| Income tax | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(1,096)](/filings/0001493152-24-045856.md) | [52.7 d](/filings/0001641172-25-003031.md) | [(303)](/filings/0001493152-25-021861.md) | [(303)](/filings/0001493152-25-021861.md) | [(2,464)](/filings/0001493152-25-021861.md) | [(163) d](/filings/0001493152-26-012736.md) | [(207)](/filings/0001493152-26-038089.md) | [2,754](/filings/0001493152-26-038089.md) | [(77.4)](/filings/0001493152-25-021861.md) | [(89.3) d](/filings/0001493152-26-012736.md) | [(55.0)](/filings/0001493152-26-038089.md) | [(85.8)](/filings/0001493152-26-038089.md) |
| Diluted EPS | $ per share | [(0.02)](/filings/0001493152-24-045856.md) | not reported | [(0.01)](/filings/0001641172-25-011514.md) | [(0.01)](/filings/0001493152-25-011661.md) | [(0.05)](/filings/0001493152-25-021861.md) | not reported | [0.00](/filings/0001493152-26-023227.md) | [0.06](/filings/0001493152-26-038089.md) | not reported | not reported | [0.00](/filings/0001493152-26-023227.md) | [0.00](/filings/0001493152-26-038089.md) |
| Basic EPS | $ per share | [(0.02)](/filings/0001493152-24-045856.md) | not reported | [(0.01)](/filings/0001641172-25-011514.md) | [(0.01)](/filings/0001493152-25-011661.md) | [(0.05)](/filings/0001493152-25-021861.md) | not reported | [0.00](/filings/0001493152-26-023227.md) | [0.06](/filings/0001493152-26-038089.md) | not reported | not reported | [0.00](/filings/0001493152-26-023227.md) | [0.00](/filings/0001493152-26-038089.md) |

- Revenue: not reported
- Selling, general and administrative: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $k | [7.0](/filings/0001493152-23-041854.md) | [53.1](/filings/0001641172-25-003031.md) | [5.2](/filings/0001493152-24-019729.md) | [7.9](/filings/0001493152-24-032378.md) | [45.3](/filings/0001493152-24-045856.md) | [6.1](/filings/0001493152-25-011661.md) | [3.4](/filings/0001641172-25-011514.md) | [1.1](/filings/0001493152-25-011661.md) | [0.6](/filings/0001493152-25-021861.md) | [0.3](/filings/0001493152-26-038089.md) | [89.9](/filings/0001493152-26-023227.md) | [56.2](/filings/0001493152-26-038089.md) |
| Current assets | $k | [50.0](/filings/0001493152-23-041854.md) | [86.6](/filings/0001641172-25-003031.md) | [36.0](/filings/0001493152-24-019729.md) | [28.8](/filings/0001493152-24-032378.md) | [68.9](/filings/0001493152-24-045856.md) | [31.9](/filings/0001493152-26-012736.md) | [21.7](/filings/0001641172-25-011514.md) | [15.3](/filings/0001493152-25-011661.md) | [14.8](/filings/0001493152-25-021861.md) | [15.8](/filings/0001493152-26-038089.md) | [101](/filings/0001493152-26-023227.md) | [64.7](/filings/0001493152-26-038089.md) |
| Total assets | $k | [2,019](/filings/0001493152-23-041854.md) | [2,255](/filings/0001641172-25-003031.md) | [2,401](/filings/0001493152-24-019729.md) | [2,339](/filings/0001493152-24-032378.md) | [198](/filings/0001493152-24-045856.md) | [160](/filings/0001493152-26-012736.md) | [150](/filings/0001641172-25-011514.md) | [15.3](/filings/0001493152-25-011661.md) | [14.8](/filings/0001493152-25-021861.md) | [15.8](/filings/0001493152-26-038089.md) | [101](/filings/0001493152-26-023227.md) | [64.7](/filings/0001493152-26-038089.md) |
| Current liabilities | $k | [1,954](/filings/0001493152-23-041854.md) | [346](/filings/0001641172-25-003031.md) | [3,297](/filings/0001493152-24-019729.md) | [3,516](/filings/0001493152-24-032378.md) | [3,599](/filings/0001493152-24-045856.md) | [5,304](/filings/0001641172-25-003031.md) | not reported | not reported | not reported | [2,157](/filings/0001493152-26-038089.md) | not reported | [2,097](/filings/0001493152-26-038089.md) |
| Total liabilities | $k | [4,034](/filings/0001493152-23-041854.md) | [4,206](/filings/0001641172-25-003031.md) | [4,642](/filings/0001493152-24-019729.md) | [4,874](/filings/0001493152-24-032378.md) | [5,189](/filings/0001493152-24-045856.md) | [5,304](/filings/0001493152-26-012736.md) | [5,493](/filings/0001641172-25-011514.md) | [1,990](/filings/0001493152-25-011661.md) | [2,067](/filings/0001493152-25-021861.md) | [2,157](/filings/0001493152-26-038089.md) | [2,048](/filings/0001493152-26-023227.md) | [2,097](/filings/0001493152-26-038089.md) |
| Current portion of debt | $k | [1,833](/filings/0001493152-23-041854.md) | not reported | [2,851](/filings/0001493152-24-019729.md) | [3,037](/filings/0001493152-24-032378.md) | [3,118](/filings/0001493152-24-045856.md) | [4,059](/filings/0001493152-26-012736.md) | [4,161](/filings/0001641172-25-011514.md) | [1,239](/filings/0001493152-25-011661.md) | [1,264](/filings/0001493152-25-021861.md) | [1,295](/filings/0001493152-26-038089.md) | [1,328](/filings/0001493152-26-023227.md) | [1,362](/filings/0001493152-26-038089.md) |
| Short-term borrowings | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $k | [(2,015)](/filings/0001493152-24-045856.md) | [(1,952)](/filings/0001493152-26-012736.md) | [(2,241)](/filings/0001493152-25-021861.md) | [(2,535)](/filings/0001493152-25-021861.md) | [(4,990)](/filings/0001493152-25-021861.md) | [(5,144)](/filings/0001493152-26-038089.md) | [(5,343)](/filings/0001493152-26-038089.md) | [(1,975)](/filings/0001493152-26-038089.md) | [(2,052)](/filings/0001493152-25-021861.md) | [(2,142)](/filings/0001493152-26-038089.md) | [(1,947)](/filings/0001493152-26-038089.md) | [(2,032)](/filings/0001493152-26-038089.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(72.4) d](/filings/0001493152-24-045856.md) | [(78.9) d](/filings/0001641172-25-003031.md) | [(72.9)](/filings/0001641172-25-011514.md) | [(97.3) d](/filings/0001493152-25-011661.md) | [(62.6) d](/filings/0001493152-25-021861.md) | [(39.2) d](/filings/0001493152-26-012736.md) | [(43.7)](/filings/0001493152-26-023227.md) | [(66.8) d](/filings/0001493152-26-038089.md) | [(31.0) d](/filings/0001493152-25-021861.md) | [(26.2) d](/filings/0001493152-26-012736.md) | [(139)](/filings/0001493152-26-023227.md) | [(33.6) d](/filings/0001493152-26-038089.md) |
| Capital expenditure | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [46.9](/filings/0001493152-23-041854.md) | [46.9](/filings/0001493152-24-019729.md) | [46.9](/filings/0001493152-24-032378.md) | [46.9](/filings/0001493152-24-045856.md) | [46.9](/filings/0001641172-25-011514.md) | [46.9](/filings/0001493152-25-011661.md) | [46.9](/filings/0001493152-25-021861.md) | [46.9](/filings/0001493152-26-023227.md) | [47.8](/filings/0001493152-26-038089.md) | [46.9](/filings/0001493152-25-021861.md) | [47.4](/filings/0001493152-26-023227.md) | [49.3](/filings/0001493152-26-038089.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 49,332,455 at 2026-08-14, from the cover of the [10-Q filed 2026-08-14](/filings/0001493152-26-038089.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:28 ET. No prices; not investment advice.